US › Healthcare

Estrella Immunopharma Inc. (ESLA)

US · Healthcare · Biotechnology

$0.43-19.63%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.3M

EPS

$-0.05

EPS estimate

$-0.09

EPS came in at -0.05 against a street estimate of -0.09 — a beat of 44.4%.

Key statistics

Market cap

$13.7M

Forward P/E

0.0

P/B

4.13

Book value

$-0.17

EPS (TTM)

$-0.24

52-week high

$3.15

52-week low

$0.29

50-day MA

$0.61

200-day MA

$1.04

Beta

0.93

Analyst view

with an average price target of $12.00.

Shareholding

Insiders

60.42%

Institutions

11.14%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.14%
Vanguard Capital Management, LLC	0.96%
Geode Capital Management, LLC	0.32%
Vanguard Fiduciary Trust Co	0.15%
BlackRock Inc	0.12%
State Street Corp	0.10%
Renaissance Technologies Corp	0.09%
Northern Trust Corp	0.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Estrella Immunopharma Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.